Biomolecular Staging: Reality or Future Perspective?

  • Paolo Bechi
Part of the Updates in Surgery book series (UPDATESSURG, volume 0)


The prognosis of patients with colorectal cancer has to date been mainly predicted on the basis of clinical and histopathologic items, with the TNM stage appearing to be the most imp


Lynch Syndrome Ression Model 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Compton C, Fenoglio-Preiser CM, Fielding LP (2000) American Joint Committee on Cancer Prognostic Factors Consensus Conference Colorectal Working Group. Cancer 88:1739–1757CrossRefPubMedGoogle Scholar
  2. 2.
    Roukos DH, Murray S, Briasoulis E (2007) Molecular genetic tools shape a roadmap towards a more accurate prognostic prediction and personalized management of cancer. Cancer Biol Ther 6:308–312CrossRefPubMedGoogle Scholar
  3. 3.
    Compton CC (2003) Colorectal carcinoma: diagnostic, prognostic, and molecular features. Mod Pathol 6:376–388CrossRefGoogle Scholar
  4. 4.
    Treanor D, Quirke P (2007) Pathology of colorectal cancer. Clin Oncol 19:769–776CrossRefGoogle Scholar
  5. 5.
    Klump B, Nehls O, Okech T et al (2004) Molecular lesions in colorectal cancer: impact on prognosis? Int J Colorectal Dis 19:23–42CrossRefPubMedGoogle Scholar
  6. 6.
    Kahlenberg MS, Stoler DL, Rodriguez-Bigas MA et al (2000) p53 tumor suppressor gene mutations predict decreased survival of patients with sporadic colorectal carcinoma. Cancer 88:1814–1819CrossRefPubMedGoogle Scholar
  7. 7.
    Schwandner O, Schiedeck THK, Bruch H-P et al (2000) p53 and Bcl-2 as significant predictors of recurrence and survival in rectal cancer. Eur J Cancer 36:348–356CrossRefPubMedGoogle Scholar
  8. 8.
    Hilska M, Collan YU, Path FRC et al (2005) The significance of tumor markers for proliferation and apoptosis in predicting survival in colorectal cancer. Dis Colon Rectum 48:2197–2208CrossRefPubMedGoogle Scholar
  9. 9.
    Lan Y, Chang S, Li A et al (2007) p53 protein accumulation as a prognostic marker in sporadic colorectal cancer. Int J Colorectal Dis 22:499–506CrossRefPubMedGoogle Scholar
  10. 10.
    Grizzle WE, Manne U, Weiss HL et al (2002) Molecular staging of colorectal cancer in African-American and Caucasian patients using phenotypic expression of p53, bcl-2, MUC-1 and p-27 (kip-1). Int J Cancer 97:403–409CrossRefPubMedGoogle Scholar
  11. 11.
    Kressner U, Bjorheim J, Westring S (1998) ki-ras mutations and prognosis in colorectal cancer. Eur J Cancer 34:518–521CrossRefPubMedGoogle Scholar
  12. 12.
    Andreyev HJNA, Norman AR, Cunningham D et al (1998) Kirsten ras mutations in patients with colorectal cancer: the multicenter “RASCAL” study. J Natl Cancer Inst 90:675–684CrossRefPubMedGoogle Scholar
  13. 13.
    McKay JA, Douglas JJ, Ross VG et al (2002) Analysis of key cell-cycle checkpoint proteins in colorectal tumours. J Pathol 196:386–393CrossRefPubMedGoogle Scholar
  14. 14.
    Polakis P (2000) Wnt signalling and cancer. Genes Dev 14:1837–1851PubMedGoogle Scholar
  15. 15.
    Bienz M, Clevers H (2000) Linking colorectal cancer to Wnt signalling. Cell 103:311–320CrossRefPubMedGoogle Scholar
  16. 16.
    Ikeguchi M, Makimo M, Kaibara N (2001) Clinical significance of E-cadherin-catenin complex expression in metastatic foci of colorectal carcinoma. J Surg Oncol 77:201–207CrossRefPubMedGoogle Scholar
  17. 17.
    Jung A, Schrauder M, Oswald U et al. (2001) The invasion front of human colorectal adenocarcinomas shows co-localisation of nuclear beta-catenin, cyclin D1 and p16INK4A and is a region of low proliferation. Am J Pathol 159:1613–1617PubMedGoogle Scholar
  18. 18.
    Xie D, Sham JS, Zeng WF et al (2003) Heterogeneous expression and association of betacatenin, p16 and c-myc in multistage colorectal tumorigenesis and progression detected by tissue microarray. Int J Cancer 107:896–902CrossRefPubMedGoogle Scholar
  19. 19.
    Araujo SE, Bernardo WM, Habr-Gama A et al (2007) DNA ploidy status and prognosis in colorectal cancer: a meta-analysis of published data. Dis Colon Rectum 50:1800–1810CrossRefPubMedGoogle Scholar
  20. 20.
    Berczi C, Bocsi J, Bartha I et al (2002) Prognostic value of DNA ploidy status in patients with rectal cancer. Anticancer Res 22:3737–3741PubMedGoogle Scholar
  21. 21.
    Muto T, Bussey HJ, Morson BC (1975) The evolution of cancer of the colon and rectum. Cancer 36:2251–2270CrossRefPubMedGoogle Scholar
  22. 22.
    Vogelstein B, Fearon ER, Hamilton SR et al (1988) Genetic alterations during colorectal-tumor development. N Engl J Med 319: 525–532CrossRefPubMedGoogle Scholar
  23. 23.
    Rodrigues NR, Rowan A, Smith ME et al (1990) p53 mutations in colorectal cancer. Proc Natl Acad Sci USA 87:7555–7559CrossRefPubMedGoogle Scholar
  24. 24.
    Mutch MG (2007) Molecular profiling and risk stratification of adenocarcinoma of the colon. J Surg Oncol 96:693–703CrossRefPubMedGoogle Scholar
  25. 25.
    Lynch HT, de la Chapelle A (2003) Hereditary colorectal cancer. N Engl J Med 348:919–932CrossRefPubMedGoogle Scholar
  26. 26.
    Samowitz WS, Albertsen H, Herrick J et al (2005) Evaluation of a large, population based sample supports a CpG island methylator phenotype in colon cancer. Gastroenterology 129:837–845CrossRefPubMedGoogle Scholar
  27. 27.
    Qiu LX, Tang QY, Bai JL et al (2008) Predictive value of thymidylate synthase expression in advanced colorectal cancer patients receiving fluoropyrimidine-based chemotherapy: evidence from 24 studies. Int J Cancer 123:2384–2389CrossRefPubMedGoogle Scholar
  28. 28.
    Jover R, Zapater P, Castells A et al for the Gastrointestinal Oncology Group of the Spanish Gastroenterological Association (2009) The efficacy of adjuvant chemotherapy with 5-Fluorouracil in colorectal cancer depends on the mismatch repair status. Eur J Cancer 45:365–373CrossRefPubMedGoogle Scholar
  29. 29.
    Bardelli A, Siena S (2010) Molecular mechanisms of resistance to cetuximab and panitumumab in colorectal cancer. J Clin Oncol 28:1254–1261CrossRefPubMedGoogle Scholar
  30. 30.
    Bokemeyer C, Bondarenko I, Makhson A et al (2009) Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer. J Clin Oncol 27:663–671CrossRefPubMedGoogle Scholar
  31. 31.
    Van Cutsem E, Köhne CH, Hitre E et al (2009) Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med 360:1408–1417CrossRefPubMedGoogle Scholar
  32. 32.
    Tahara E (2007) Growth factors and oncogenes in gastrointestinal cancers. In: Meyers RA (ed) Cancer. Wiley-VCH, Weinheim, pp. 286–296Google Scholar
  33. 33.
    Pang RWC, Joh JW, Johnson PJ (2008) Biology of hepatocellular carcinoma. Ann Surg Oncol 15:962–971CrossRefPubMedGoogle Scholar
  34. 34.
    Aravalli RN, Steer CJ, Cressman EN (2008) Molecular mechanisms of hepatocellular carcinoma. Hepatology 48:2047–2063CrossRefPubMedGoogle Scholar
  35. 35.
    Wild CP, Montesano R (2009) A model of interaction: aflatoxins and hepatitis viruses in liver cancer aetiology and prevention Cancer Lett 286:22–28Google Scholar
  36. 36.
    Mínguez B, Tovar V, Chiang D et al (2009) Pathogenesis of hepatocellular carcinoma and molecular therapies. Curr Opin Gastroenterol 25:186–194CrossRefPubMedGoogle Scholar
  37. 37.
    Llovet JM, Ricci S, Mazzaferro V et al for the SHARP Investigators Study Group (2008) Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 359:378–390Google Scholar
  38. 38.
    Siegel AB, Cohen EI, Ocean A et al (2008) Phase II trial evaluating the clinical and biologic effects of bevacizumab in unresectable hepatocellular carcinoma. J Clin Oncol 26:2992–2998CrossRefPubMedGoogle Scholar
  39. 39.
    Bardeesy N, DePinho RA (2002) Pancreatic cancer biology and genetics. Nature 2:897–909Google Scholar
  40. 40.
    Hruban RH, Goggins M, Parsons J, Kern SE (2000) Progression model for pancreatic cancer. Clin Cancer Res 6:2696–2972Google Scholar
  41. 41.
    Yamashita S (2009) Molecular targeted therapy for thyroid cancer in Japan: a call to reduce the backlog. Endocr J 56:919–920CrossRefPubMedGoogle Scholar
  42. 42.
    Chevillard S, Ugolin N, Vielh P et al (2004) Gene expression profiling of differentiated thyroid neoplasms: diagnostic and clinical implications. Clin Cancer Res 10:6586–6597CrossRefPubMedGoogle Scholar
  43. 43.
    Hou P, Ji M, Xing M (2008) Association of PTEN gene methylation with genetic alterations in the phosphatidylinositol 3-kinase/AKT signaling pathway in thyroid tumors. Cancer 113:2440–2447CrossRefPubMedGoogle Scholar
  44. 44.
    Smallridge RC, Marlow LA, Copland JA (2009) Anaplastic thyroid cancer: molecular pathogenesis and emerging therapies. Endocr Relat Cancer 16:17–44CrossRefPubMedGoogle Scholar
  45. 45.
    Polyak K (2008) Is breast tumor progression really linear? Clin Cancer Res 14:339–341CrossRefPubMedGoogle Scholar
  46. 46.
    Polyak K (2007) Breast cancer: origins and evolution. J Clin Invest 117:3155–3163CrossRefPubMedGoogle Scholar
  47. 47.
    Di Cosimo S (2009) Controversies in breast cancer: the mammalian target of rapamycin as a target for breast cancer therapy. Breast Cancer Research 11[Suppl 3]: S25CrossRefPubMedGoogle Scholar
  48. 48.
    Seni T, Jatoi I (2008) An overview of the role of prophylactic surgery in the management of individuals with a hereditary cancer predisposition. Surg Clin N Am 88:739–758CrossRefGoogle Scholar
  49. 49.
    Schellhaas E, König C, Frank-Raue K et al (2009) Long-term outcome of “prophylactic therapy” for familial medullary thyroid cancer. Surgery 146:906–912CrossRefPubMedGoogle Scholar
  50. 50.
    Skinner MA, Moley JA, Dilley WG et al (2005) Prophylactic thyroidectomy in multiple endocrine neoplasia type 2A. N Engl J Med 353:1105–1113CrossRefPubMedGoogle Scholar
  51. 51.
    Guillem JG, Wood WC, Moley JF et al (2006) ASCO/SSO Review of current role of risk-reducing surgery in common hereditary cancer syndromes. J Clin Oncol 24:4642–4660CrossRefPubMedGoogle Scholar
  52. 52.
    Meijers-Heijboer H, Van Geel B, van Putten WLJ et al (2001) Breast cancer after prophylactic bilateral mastectomy in women with a BRCA1 or BRCA2 mutation. N Engl J Med 345:159–164CrossRefPubMedGoogle Scholar
  53. 53.
    Schmeler KM, Lynch HT, Chen LM et al (2006) Prophylactic surgery to reduce the risk of gynecologic cancers in the Lynch Syndrome. N Engl J Med 354:261–269CrossRefPubMedGoogle Scholar
  54. 54.
    Ramsoekh D, Wagner A, van Leerdam ME et al (2009) Cancer risk in MLH1, MSH1 and MSH6 mutation carriers; different risk profile may influence clinical management. Hered Cancer Clin Pract 23:17CrossRefGoogle Scholar
  55. 55.
    Lynch HT, Grady W, Suriano G, Huntsman D (2005) Gastric cancer: new genetic development. J Surg Oncol 90:114–133CrossRefPubMedGoogle Scholar
  56. 56.
    Ziogas D, Roukos DH (2009) CDH1 testing: can it predict the prophylactic or therapeutic nature of total gastrectomy in hereditary diffuse gastric cancer? Ann Surg Oncol 16:2678–2681CrossRefPubMedGoogle Scholar
  57. 57.
    Schulte am Esch J, Knoefel WT, Klein M et al (2005) Portal application of autologous CD 133+ bone marrow cells to the liver: a novel concept to support hepatic regeneration. Stem Cell 23:463–470CrossRefGoogle Scholar
  58. 58.
    Fürst G, Schulte am Esch J, Poll LW et al (2007) Portal vein embolization and autologous CD133+ bone marrow stem cells for liver regeneration: initial experience. Radiology 243:171–179CrossRefPubMedGoogle Scholar
  59. 59.
    Kuhlmann KF, van Till JW, Boermeester MA et al (2007) Evaluation of matrix metalloproteinase 7 in plasma and pancreatic juice as a biomarker for pancreatic cancer. Cancer Epidemiol Biomarkers Prev 16:886–891CrossRefPubMedGoogle Scholar
  60. 60.
    Yan L, McFaul C, Howes N et al (2005) Molecular analysis to detect pancreatic ductal adenocarcinoma in high-risk groups. Gastroenterology 128:2124–2130CrossRefPubMedGoogle Scholar
  61. 61.
    Walgenbach KJ, Voigt M, Riabikhin AW et al (2001) Tissue engineering in plastic reconstructive surgery. Anat Rec 263:372–378CrossRefPubMedGoogle Scholar
  62. 62.
    Mizuno H (2009) Adipose-derived stem cells for tissue repair and regeneration: ten years of research and a literature review. J Nippon Med Sch 76:56–66CrossRefPubMedGoogle Scholar
  63. 63.
    Yoshimura K, Sato K, Aoi N et al (2008) Cell-assisted lipotransfer for cosmetic breast augmentation: supportive use of adipose-derived stem/stromal cells. Aesth Plast Surg 32:48–55CrossRefGoogle Scholar
  64. 64.
    Bechi P, Balzi M, Becciolini A et al (1996) Helicobacter pylori and cell proliferation of the gastric mucosa: possible implications for gastric carcinogenesis. Am J Gastroenterol 91:271–276PubMedGoogle Scholar
  65. 65.
    Bechi P, Balzi M, Becciolini A et al (1991) Gastric cell proliferation kinetics and bile reflux after partial gastrectomy. Am J Gastroenterol 86:1424–1432PubMedGoogle Scholar
  66. 66.
    Volpi A, De Paola F, Nanni O et al (2000) Prognostic significance of biologic markers in nodenegative breast cancer patients: a prospective study. Breast Cancer Res Treat 63:181–192CrossRefPubMedGoogle Scholar
  67. 67.
    Amadori D, Nanni O, Volpi A et al (2008) Phase III randomized multicenter study on the effects of adjuvant CMF in patients with node-negative, rapidly proliferating breast cancer: twelveyear results and retrospective subgroup analysis. Breast Cancer Res Treat 108:259–264CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag Italia 2011

Authors and Affiliations

  • Paolo Bechi
    • 1
  1. 1.Department of Medical and Surgical Critical CareUniversity of Florence and Regional Reference Centre of Tuscany for Locoregional Perfusion TherapiesFlorenceItaly

Personalised recommendations